1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

04 Apr 2024
Admin
News Article

Dosing Begins in Clinical Study of YOLT-101 for FH Therapy

Initial Dosing of Patient Commences in Clinical Study Investigating YOLT-101 for FH Therapy

Overview

YolTech Therapeutics has announced a significant milestone in its development of YOLT-101, an in vivo genome editing candidate for treating Familial Hypercholesterolemia (FH). The company has initiated an Investigator-Initiated Trial (IIT) by dosing the first patient with YOLT-101.

FH is a genetic disorder affecting the body's ability to remove low-density lipoprotein (LDL) cholesterol from the bloodstream, leading to an increased risk of early heart disease.

About YOLT-101

YOLT-101, developed independently by YolTech, targets specific genetic mutations associated with FH using advanced gene editing technology and lipid nanoparticle (LNP) delivery.
Preclinical studies in non-human primate (NHP) models have shown significant and sustained reduction in LDL-C levels for nearly two years after a single dose.

About Trial

The clinical trial initiated by investigators is a single-arm, open-label, dose-escalation study. Its primary objectives include assessing the safety and tolerability of YOLT-101, determining the Optimal Biologically Active Dose (OBD), and preliminarily evaluating its impact on lipid and lipoprotein levels in FH patients.

YolTech Potential of YOLT-101

Dr. Yuxuan Wu, Founder and CEO of YolTech, expressed optimism about the potential of YOLT-101 to revolutionize treatment for FH patients.
YolTech is committed to advancing the clinical development of YOLT-101 and collaborating closely with regulatory authorities, healthcare professionals, and patient advocacy groups.

YOLT-101 & Current Studies

YOLT-101 is an in vivo liver-based editing therapy designed to permanently deactivate the PCSK9 gene, thereby reducing disease-driving LDL-C levels.
It is currently undergoing evaluation in the IIT clinical trial for patients with high-risk heterozygous FH, established atherosclerotic cardiovascular disease (ASCVD), and uncontrolled LDL-C levels on standard-of-care therapy.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!